About: Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
Creator	Fafi-Kremer, Samira Schneider, Francis Collange, Olivier Danion, François Gallais, Floriane Meziani, Ferhat Schmidt-Mutter, Catherine Benotmane, Ilies Bilbault, Pascal De Sèze, Jérôme Velay, Aurelie Wendling, Marie
Source	Elsevier; PMC
abstract	Rapid and accurate diagnosis is crucial for successful outbreak containment. During the current COVID-19 public health emergency, the gold standard for SARS-CoV-2 infection diagnosis is the detection of viral RNA. Additional diagnostic methods enabling the detection of current or past SARS-CoV-2 infection would be highly beneficial. We assessed two immunochromatographic lateral flow assays (LFA-1, LFA-2) and two ELISA kits (IgA /IgG ELISA-1, IgM /IgG ELISA-2) using 325 samples: serum samples from PCR-confirmed COVID-19 hospitalized patients (n = 55) and healthcare workers (n = 143) and 127 samples from negative controls. Diagnostic performances were assessed according to days after symptom onset (dso) and the antigenic format used by manufacturers. Clinical sensitivities varied greatly among the assays, showing poor mutual agreement. After 15 dso, ELISA-1 (Euroimmun) and LFA-1 (Biosynex) combining IgM and IgG detection showed the best performances. A thorough selection of serological assays for the detection of ongoing or past infections is advisable.
has issue date	2020-08-21(xsd:dateTime)
bibo:doi	10.1016/j.diagmicrobio.2020.115181
has license	no-cc
sha1sum (hex)	320f87237947edf11bb868d83a81a283d721c2d8
schema:url	https://doi.org/10.1016/j.diagmicrobio.2020.115181
resource representing a document's title	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
has PubMed Central identifier	PMC7441068
schema:publication	Diagn Microbiol Infect Dis
resource representing a document's body	covid:320f87237947edf11bb868d83a81a283d721c2d8#body_text
is schema:about of	named entity 'highly' named entity 'assessed' named entity 'Performances' named entity 'LFA-1' named entity 'assays' named entity 'Journal' named entity 'onset' named entity 'clinical' named entity 'IgG' named entity 'Revised' named entity 'SARS-CoV-2' named entity 'ongoing' named entity 'assays' named entity 'samples' named entity 'onset' named entity 'healthcare' named entity 'symptom' named entity 'format' named entity 'selection' named entity 'infection' named entity 'samples' named entity 'Highlights' named entity 'Journal' named entity 'samples' named entity 'assessed' named entity 'accurate' named entity 'performance' named entity 'performance' named entity 'IgM' named entity 'lateral flow assays' named entity 'dso' named entity 'symptom' named entity 'diagnostic methods' named entity 'infection' named entity 'IgM' named entity 'PCR' named entity 'IgG' named entity 'immunochromatographic' named entity 'LFA-1' named entity 'symptom' named entity 'serological' named entity 'COVID' named entity 'infections' named entity 'antigenic' named entity 'LFA-2' named entity 'IgM' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'nucleocapsid' named entity 'serum samples' named entity 'IgM' named entity 'false-positive' named entity 'LFA-1' named entity 'dso' named entity 'RT-PCR' named entity 'nucleocapsid' named entity 'Serological' named entity 'dso' named entity 'LFA-1' named entity 'reproducibility' named entity 'IgG' named entity 'LFA-2' named entity 'nasopharyngeal swab' named entity 'ICU' named entity 'IgA' named entity 'antibodies' named entity 'IgG' named entity 'rheumatoid factor' named entity 'IgM' named entity 'polymerase chain reaction' named entity 'IgA' named entity 'nucleocapsid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software